Comment
doi: 10.1016/S1474-4422(23)00163-1.
Valbenazine as treatment for Huntington's disease chorea
Affiliations
- PMID: 37210087
- DOI: 10.1016/S1474-4422(23)00163-1
Item in Clipboard
Comment
Valbenazine as treatment for Huntington's disease chorea
Lancet Neurol.
2023 Jun.
No abstract available
Comment on
-
Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington's disease (KINECT-HD): a phase 3, randomised, double-blind, placebo-controlled trial.Lancet Neurol. 2023 Jun;22(6):494-504. doi: 10.1016/S1474-4422(23)00127-8. Lancet Neurol. 2023. PMID: 37210099 Clinical Trial.
Similar articles
-
Valbenazine for the treatment of chorea associated with Huntington's disease.Expert Opin Pharmacother. 2025 Feb;26(2):127-132. doi: 10.1080/14656566.2024.2445728. Epub 2024 Dec 30. Expert Opin Pharmacother. 2025. PMID: 39729631 Review.
-
Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington's disease (KINECT-HD): a phase 3, randomised, double-blind, placebo-controlled trial.Lancet Neurol. 2023 Jun;22(6):494-504. doi: 10.1016/S1474-4422(23)00127-8. Lancet Neurol. 2023. PMID: 37210099 Clinical Trial.
-
Treatment of chorea associated with Huntington's disease: focus on tetrabenazine.Consult Pharm. 2009 Jul;24(7):524-37. doi: 10.4140/tcp.n.2009.524. Consult Pharm. 2009. PMID: 19689181 Review.
-
VMAT2 inhibitors for the treatment of hyperkinetic movement disorders.Pharmacol Ther. 2020 Aug;212:107580. doi: 10.1016/j.pharmthera.2020.107580. Epub 2020 May 23. Pharmacol Ther. 2020. PMID: 32454050 Review.
-
Tetrabenazine: for chorea associated with Huntington's disease.CNS Drugs. 2011 Dec 1;25(12):1073-85. doi: 10.2165/11208330-000000000-00000. CNS Drugs. 2011. PMID: 22133328
Cited by
-
Huntington's Disease: Latest Frontiers in Therapeutics.Curr Neurol Neurosci Rep. 2024 Aug;24(8):255-264. doi: 10.1007/s11910-024-01345-y. Epub 2024 Jun 11. Curr Neurol Neurosci Rep. 2024. PMID: 38861215 Review.
-
From Brain to Blood: Uncovering Potential Therapeutical Targets and Biomarkers for Huntington's Disease Using an Integrative RNA-Seq Analytical Platform (BDASeq®).Cells. 2025 Jun 25;14(13):976. doi: 10.3390/cells14130976. Cells. 2025. PMID: 40643497 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
